Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000536746 | SCV000633731 | uncertain significance | Hereditary hemochromatosis | 2024-11-18 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 130 of the HFE protein (p.Asn130Ser). This variant is present in population databases (rs201885016, gnomAD 0.003%). This missense change has been observed in individual(s) with clinical features of HFE-related conditions (internal data). ClinVar contains an entry for this variant (Variation ID: 461191). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt HFE protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003258860 | SCV003946952 | uncertain significance | Inborn genetic diseases | 2023-05-15 | criteria provided, single submitter | clinical testing | The c.389A>G (p.N130S) alteration is located in exon 3 (coding exon 3) of the HFE gene. This alteration results from a A to G substitution at nucleotide position 389, causing the asparagine (N) at amino acid position 130 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |